Lexicon Pharmaceuticals(US:LXRX)2025-11-06 13:30Business Highlights - Pilavapadin is progressing towards Phase 3 registrational trials[5, 6] - Lexicon aims to submit an IND for LX9851 in obesity[5] - Enrollment is accelerating in the SONATA Phase 3 study for HCM[5, 6, 23] - Lexicon is evaluating the potential path forward for Zynquista[5, 10] - Lexicon is seeking partners for appropriate assets[5, 6] Sotagliflozin - Sotagliflozin was recently approved in UAE for recent and worsening heart failure[9] - Submissions for Sotagliflozin have been made in Saudi Arabia, Canada, Australia, and New Zealand[9] - Filings in Mexico and Malaysia are expected by year-end[9] - Lexicon may achieve remaining near-term development milestones of $30 million related to LX9851[9, 31] Financial Overview - As of September 30, 2025, cash, cash equivalents, short-term investments, and restricted cash totaled $145 million[27] - Total assets as of September 30, 2025, were $2059 million[27] - Total debt as of September 30, 2025, was $565 million[27] - Q3 2025 total revenues were $142 million, including $132 million in licensing revenue[27] - Q3 2025 net loss was $128 million, or $004 per common share[27] - Total 2025 operating expenses are expected to be between $105 million and $115 million[29]